|
Back to Press Releases
Madeira Therapeutics to Present at BIO International Convention
(LEAWOOD, KS; May 6, 2009) - Madeira Therapeutics, a Kansas-based company specializing in pediatric pharmaceuticals, announced today that Peter Joiner, Madeira president and chief executive officer, will present an overview of the company at the annual BIO International Convention on May 20, 2009, from 9:00-9:15 am in room 316 at the World Congress Center in Atlanta, Georgia.
Madeira Therapeutics currently has two pediatric products in development: MT-001, the first ever liquid preparation of a statin for children and the elderly, and MT-003, a liquid preparation of an analgesic for the treatment of acute pain. Madeira Therapeutics is solely dedicated to providing real pediatric medications - one of the few drug development companies with a specialized focus on this niche market.
More than 180 companies working on innovations to heal, fuel, and feed the world will be making 15-minute presentations on their technology and accomplishments. The presentations are grouped by major biotechnology markets to give attendees a great way to get quick insight into companies of interest. Company presentations are open to all attendees at no charge and will take place in Building A, Level 3.
The BIO International Convention is the largest global event for the biotechnology industry, offers key networking and partnering opportunities, and provides insight on major trends affecting the industry. Madeira Therapeutics will be exhibiting alongside KansasBio at booth #3707.
About Madeira Therapeutics
Madeira Therapeutics, LLC, is a privately held, specialty pharmaceutical company focused on providing safe and effective medicine to pediatric and geriatric patients, parents and the healthcare professionals that serve them. The Madeira strategy focuses on reformulating adult drugs for better dosage control in children. Madeira utilizes the FDA's 505(b)(2) approval method, which relies in part on the regulatory agency's findings for a drug previously approved for adults, thereby shortcutting FDA approval by years and saving tens of millions of dollars in development costs. The company's lead program, MT-001, is the first ever liquid preparation of a statin developed for the geriatric and pediatric population. The second product is MT-003 for acute pain relief. For more information, please visit www.madeiratherapeutics.com.
|
